ASLAN Pharmaceuticals Limited
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ASLAN Pharmaceuticals Limited (Nasdaq: ASLN) is a clinical-stage biopharmaceutical company focused on immunology, developing novel treatments for autoimmune diseases such as atopic dermatitis and alopecia areata; its lead product candidate, eblasakimab, is a potential first-in-class monoclonal antibody targeting the IL-13 receptor alpha 1 subunit in Phase 2 trials for moderate-to-severe atopic dermatitis, including the TREK-AD and TREK-DX studies evaluating efficacy in dupilumab-experienced patients; farudodstat, a potent oral dihydroorotate dehydrogenase (DHODH) inhibitor, advances in a Phase 2a FAST-AA trial for alopecia areata with interim data expected mid-2024 and positive safety profile; earlier pipeline assets include varlitinib ditosylate, a small-molecule inhibitor of EGFR, HER2, and HER4 for advanced biliary tract cancer, and ASLAN-002 targeting MST1R and c-Met in malignant solid neoplasms. The company, founded in 2010 and headquartered in Singapore with operations in San Mateo, California, targets patient populations in autoimmune and inflammatory conditions across global markets, particularly Asia and the United States through clinical collaborations. Recent developments include a May 2024 expansion of its research collaboration with Zenyaku Kogyo Co., Ltd. for eblasakimab's development and commercialization in Japan building on a June 2023 commercial agreement; a March 2024 $5 million registered direct offering to support research and development; positive interim Phase 2 results for eblasakimab in dupilumab-experienced atopic dermatitis patients in April 2024; a February 2024 positive European Patent Office opinion on farudodstat's composition of matter patent extending protection to at least 2043; and a July 2024 voluntary liquidation filing for its sole operating subsidiary, ASLAN Pharmaceuticals Pte Ltd, following strategic review amid pipeline prioritization and corporate restructuring.
Critical Contrast: ASLAN Pharmaceuticals (NASDAQ:ASLN) vs. Argos Therapeutics (OTCMKTS:ARGSQ)
Analyzing ASLAN Pharmaceuticals (NASDAQ:ASLN) & CannTrust (OTCMKTS:CNTTF)
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
All You Need to Know About ASLAN Pharmaceuticals (ASLN) Rating Upgrade to Buy
Here's Why ASLAN Pharmaceuticals (ASLN) Could be Great Choice for a Bottom Fisher
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement